Our Technology
Advanced non-invasive monitoring for early detection of hemorrhage
Our proprietary Continuous Spectral Imaging (CSI) device is a breakthrough in non-invasive hemodynamic monitoring. Using advanced optical technology, it provides real-time insights into vital physiological parameters.
The CSI technology measures key physiological parameters, including:
- Hemoglobin concentration and oxygen saturation: Provides insights into oxygen-carrying capacity and arterial oxygen levels.
- Blood volume changes in real-time: Detects fluctuations indicative of hemorrhage or vascular shifts.
- Tissue perfusion levels: Monitors blood flow efficiency to tissues.
- Microvascular blood flow: Assesses the dynamics of blood flow in small vessels, critical for evaluating tissue health.
Advanced Technology
The CSI system utilizes laser speckle imaging and spectroscopic analysis to measure vital parameters continuously and non-invasively. This technology is particularly effective for early detection and monitoring of hemorrhage, as it can detect subtle changes in tissue perfusion and oxygenation before traditional vital signs show significant changes.
A key advantage of our technology is its ability to work effectively across all skin types, as validated by extensive research showing that epidermal melanin content has minimal impact on measurement accuracy. This makes the CSI device a reliable tool for monitoring patients of all ethnicities in both clinical and emergency settings.
Early Detection Capabilities
Clinical studies have demonstrated the CSI device's ability to detect hemorrhage progression significantly earlier than conventional monitoring methods. The system's continuous monitoring capability enables healthcare providers to:
- Identify subtle changes in tissue perfusion
- Monitor treatment effectiveness in real-time
- Make timely, data-driven clinical decisions
- Improve patient outcomes through early intervention
Product Evolution
From laboratory concept to commercial product, our technology is evolving through three generations
Gen 1
Proof of Concept
Our journey began at UC Irvine with a benchtop prototype that validated our core technology. This initial version demonstrated the feasibility of using diffuse reflectance spectroscopy for hemorrhage detection.
Gen 2
We're HereWorking Prototype
Our second-generation model, developed in-house, features a compact, portable design with enhanced sensors and real-time processing capabilities. Currently, UMass Medical School is assisting in clinically validating this version to ensure its efficacy and reliability in real-world applications.
Currently running clinical validation studies while preparing for Gen 3 development starting January 2025.
Gen 3
Commercial Product
In partnership with WPI, our upcoming commercial version will feature a miniaturized, wearable design with wireless connectivity and extended battery life. Development begins January 2025.
Research Papers
Explore published research related to our technology
